Cancer Survivors Show Increased Use of Antidepressants and Anxiolytics

View at publisher Summarise with VIRAT
Authors: Catlin Nalley
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Cancer survivors are more likely than their peers without a history of cancer to be treated with medications for depression and anxiety. However, that increased use does not extend equally across all patient populations, according to a recent study (JAMA Netw Open 2025; doi.org/10.1001/jamanetworkopen.2025.27585). In a national analysis of more than 5,000 adult cancer survivors, non-Hispanic Black patients were significantly less likely to use antidepressants or anxiolytics than non-Hispanic White survivors, revealing a persistent gap in mental health treatment within survivorship care. Differences were also observed across cancer types, suggesting that both social and disease-related factors shape access to pharmacologic mental health support. These findings arrive at a time when the oncology community is paying closer attention to the long-term psychological burden of cancer. Advances in early detection and treatment have led to a rapidly expanding survivor population, many of whom live for years or decades after diagnosis. For these individuals, depression and anxiety are not uncommon and may arise from fear of recurrence, chronic treatment effects, financial toxicity, and disruptions to work and family life. Left unaddressed, these conditions can compromise quality of life and interfere with engagement in ongoing cancer care. Although professional societies increasingly emphasize distress screening and integrated psychosocial care, real-world practice often falls short—particularly for patients from historically marginalized communities. Prior studies in noncancer populations have documented racial and ethnic disparities in the diagnosis and treatment of mood and anxiety disorders, including lower rates of pharmacologic treatment among Black patients. Whether similar patterns persist among cancer survivors, despite their frequent contact with the healthcare system, has remained an important and unresolved question. The current study explores this issue using nationally representative data to assess antidepressant and anxiolytic use among adult cancer survivors, with a focus on sociodemographic characteristics and cancer type. By identifying who is, and is not, receiving medication-based mental health treatment, the findings highlight critical opportunities for oncologists to address inequities in survivorship care and to ensure that mental health needs are recognized and treated as an integral part of cancer outcomes. Research Details Study author Nosayaba Osazuwa-Peters, BDS, PhD, of Duke Health in Durham, North Carolina, and colleagues noted, “Depression and anxiety disproportionately impact cancer survivors. Sociodemographic factors frequently impact access to cancer care; however, it is unclear if these factors are associated with access to pharmacological care for mental and behavioral health conditions.” Therefore, they sought to better understand how “antidepressant and anxiolytic use among cancer survivors compared with the general U.S. population and to identify associations between sociodemographic factors and medication use.” The investigators conducted a cross-sectional analysis using data from the National Health Interview Survey (NHIS), a long-standing, nationally representative survey of the civilian, noninstitutionalized U.S. population. Analyses were performed in January 2024 and drew on NHIS data collected between 2016 and 2018. According to the authors, this 3-year window was intentionally selected to maintain consistency in survey design and content, particularly given substantial restructuring of the NHIS in 2019 and declining response rates following the COVID-19 pandemic. NHIS collects self-reported health information annually through in-person household interviews. For the present study, person-level and adult-level files were combined for each year. In addition, Adult Functioning and Disability (AFD) supplement files were incorporated for 2016 and 2017; all adult respondents completed the AFD supplement in 2018. These harmonized datasets were then pooled across years to create a single analytic cohort. The study included U.S. adults between the ages of 18 and 85 years. Consistent with NHIS design, individuals residing in correctional facilities, long-term care institutions, military bases, or outside the U.S. were excluded, as were those without a fixed household address. Individuals with a history of nonmelanoma skin cancer were also excluded. Eligible participants were required to have complete data for the primary outcomes of interest. The analysis focused on two primary outcomes: antidepressants and anxiolytic usage. These outcomes were derived from self-reported responses to questions asking participants whether they currently take medication for each condition. Response options included “yes,” “no,” as well as several nonresponse categories. “A binary variable was created for each outcome, in which respondents who indicated yes to the question of interest were flagged as a 1 and all other respondents were flagged as a 0,” the study authors explained. Sociodemographic variables examined in the study included age, sex, marital status, household income, educational attainment, insurance status, U.S. geographic region, survey year, length of residence in the U.S., and English-language proficiency. Race and ethnicity were self-reported. Among respondents with a cancer history, cancer type was further classified into clinically relevant categories, including breast, prostate, lung, colorectal, hematologic, head and neck, brain, cervical, pancreatic, multiple cancers, and other or unknown types. Key Findings Of the 53,117 respondents included in the study, 5,091 reported a history of cancer, while 48,026 reported no cancer history. Cancer survivors differed demographically from the noncancer population, with a higher proportion identifying as non-Hispanic White and female. Across the full sample, use of antidepressants and anxiolytics was consistently higher among individuals with a cancer history. “Respondents with a history of cancer reported taking medications for depression and anxiety at almost double the rate of respondents without a history of cancer; 748 respondents (13.8%) and 783 respondents (14.5%) with a history of cancer took medication for depression and anxiety, respectively, whereas 4,551 respondents (8.3%) and 4,838 respondents (8.9%) without a history of cancer took medication for depression and anxiety, respectively,” reported Osazuwa-Peters and colleagues. These differences persisted after adjustment for a broad range of sociodemographic factors. In fully adjusted models, cancer survivors had 32% higher odds of antidepressant use and 38% higher odds of anxiolytic use compared with the general population. However, closer examination of medication use among cancer survivors revealed inequities. Race and ethnicity emerged as significant factors in access to pharmacologic mental health treatment. Non-Hispanic Black cancer survivors were markedly less likely than non-Hispanic White survivors to report taking antidepressants or anxiolytics, even after accounting for income, insurance status, education, and other sociodemographic variables. Insurance status was also strongly associated with medication use. “Cancer survivors on Medicare (aOR: 2.20; 95% CI: 1.39-3.50) or Medicaid (aOR, 1.83; 95% CI: 1.18-2.84) were more likely to take anxiolytics compared with privately insured individuals,” the researchers noted. Social factors further shaped treatment patterns. Cancer survivors who were not married were more likely to report using medications for both depression and anxiety compared with married survivors. Those who had never married showed especially higher odds of antidepressant use. Medication use also varied by cancer type. Compared with breast cancer survivors, individuals with a history of brain cancer or pancreatic cancer had markedly higher odds of antidepressant use, and pancreatic cancer survivors were also significantly more likely to use anxiolytics. “This cross-sectional study of anxiolytic and antidepressant use among cancer survivors found that Black cancer survivors were less likely to use medications for depression and anxiety compared with White survivors after controlling for other sociodemographic characteristics,” Osazuwa-Peters and colleagues wrote in JAMA Network Open. “Given the potential impact that depression and anxiety can have on treatment outcomes, it is important to ensure equitable access to mental health for all cancer survivors independent of sociodemographic differences.” Implications & Next Steps These findings reinforce the growing recognition that mental health is a central component of cancer survivorship while also underscoring that access to treatment remains uneven. Although cancer survivors overall were more likely than the general population to use medications for depression and anxiety, substantial disparities persisted across sociodemographic groups. Differences by race and ethnicity, insurance status, marital status, and cancer type suggest that pharmacologic treatment for mental health is shaped by more than clinical need alone. Most notably, non-Hispanic Black cancer survivors were significantly less likely than non-Hispanic White survivors to use antidepressants or anxiolytics. A range of factors may contribute to this disparity, including stigma surrounding mental illness, cultural beliefs about treatment, lower levels of trust in the healthcare system, clinician bias, and reduced access to culturally concordant care. Clarifying how these factors shape treatment decisions and outcomes among cancer survivors will be critical for developing targeted, equitable interventions. As the authors emphasized, “Social determinants of health play a role in healthcare access and quality in many areas, including the increasing mental health crisis within the general U.S. population. While depression and anxiety are nationwide problems, they are especially prevalent among the cancer population.” Given the well-documented impact of depression and anxiety on survival, treatment adherence, and quality of life, they stressed that mental healthcare should be prioritized throughout the cancer continuum, from diagnosis through long-term survivorship. The disparities identified in this analysis, they noted, raise an important question: whether lower rates of medication use reflect patient preference or limited opportunity to access care. Looking ahead, the investigators concluded that more standardized and frequent mental health screening may benefit all patients, particularly cancer survivors. “Continued integration of mental health specialists into cancer centers and better awareness and recognition of the impact of mental health on cancer outcomes could solidify mental health treatment as an essential part of cancer care and help eliminate observed stigma and disparities.” Catlin Nalley is a contributing writer. Read This Article and Earn CME or NCPD! Earn continuing education credit by completing a quiz about this article. You may read the article here or on our website, then complete the quiz, answering at least 80 percent of the questions correctly to earn credit. CONTINUING MEDICAL EDUCATION INFORMATION FOR PHYSICIANS Visit http://CME.LWW.com for more information about this educational offering and to complete the CME activity. This enduring material is available to physicians in all specialties. Lippincott Continuing Medical Education Institute, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc., designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity expires March 31, 2028. The cost of the exam is $10. The payment covers processing and certificate fees. PROVIDER ACCREDITATION INFORMATION FOR NURSES Lippincott Professional Development (LPD) will award 1.0 contact hour for this Nursing Continuing Professional Development (NCPD) activity. LPD is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.0 contact hour. LPD is also an approved provider of continuing nursing education by the District of Columbia, Georgia, West Virginia, New Mexico, South Carolina, and Florida, CE Broker #50-1223. Your certificate is valid in all states. Visit www.nursingcenter.com for more information and to complete the NCPD activity. Fee: $12.95 Deadline: June 2, 2028 For nurses who wish to take the test for NCPD contact hours, visit www.nursingcenter.com/ce/OT. Learning Objectives for This Month's Activity: After participating in this activity, readers should be better able to Summarize the study results regarding antidepressant and anxiolytic use among cancer survivors. Explain the clinical implications of the findings. Disclosure: All authors, faculty, staff, and planners have no relevant financial relationships with any ineligible organizations regarding this educational activity.

Fields of Study & Subjects

Cancer survivorship and care Mental Health Treatment and Access Childhood Cancer Survivors' Quality of Life

Publication details

Journal / source
Oncology Times
Volume
48
Issue
4
Pages
20–21
Publication date
27 March 2026
Language
EN